WYE-687

WYE-687 is a drug which acts as an inhibitor of both subtypes of the mechanistic target of rapamycin (mTOR), mTORC1 and mTORC2. It is being researched for potential applications in the treatment of various forms of cancer.[1][2][3]

WYE-687
Identifiers
  • methyl N-[4-[4-morpholin-4-yl-1-[1-(pyridin-3-ylmethyl)piperidin-4-yl]pyrazolo[3,4-d]pyrimidin-6-yl]phenyl]carbamate
CAS Number
PubChem CID
ChemSpider
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC28H32N8O3
Molar mass528.617 g·mol−1
3D model (JSmol)
  • COC(=O)NC1=CC=C(C=C1)C2=NC3=C(C=NN3C4CCN(CC4)CC5=CN=CC=C5)C(=N2)N6CCOCC6
  • InChI=1S/C28H32N8O3/c1-38-28(37)31-22-6-4-21(5-7-22)25-32-26(35-13-15-39-16-14-35)24-18-30-36(27(24)33-25)23-8-11-34(12-9-23)19-20-3-2-10-29-17-20/h2-7,10,17-18,23H,8-9,11-16,19H2,1H3,(H,31,37)
  • Key:VDOCQQKGPJENHJ-UHFFFAOYSA-N

References

  1. Yu K, Toral-Barza L, Shi C, Zhang WG, Lucas J, Shor B, et al. (August 2009). "Biochemical, cellular, and in vivo activity of novel ATP-competitive and selective inhibitors of the mammalian target of rapamycin". Cancer Research. 69 (15): 6232–40. doi:10.1158/0008-5472.CAN-09-0299. PMID 19584280.
  2. Cheng F, Wang L, Shen Y, Xia J, Chen H, Jiang Y, Lu M (February 2016). "Preclinical evaluation of WYE-687, a mTOR kinase inhibitor, as a potential anti-acute myeloid leukemia agent". Biochemical and Biophysical Research Communications. 470 (2): 324–330. doi:10.1016/j.bbrc.2016.01.054. PMID 26792718.
  3. Pan XD, Gu DH, Mao JH, Zhu H, Chen X, Zheng B, Shan Y (2017). "Concurrent inhibition of mTORC1 and mTORC2 by WYE-687 inhibits renal cell carcinoma cell growth in vitro and in vivo". PLOS ONE. 12 (3): e0172555. Bibcode:2017PLoSO..1272555P. doi:10.1371/journal.pone.0172555. PMC 5336203. PMID 28257457.


This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.